For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Harpoon Therapeutics, Inc.

USPTO Granted Patents = 23

EPO Patents = 4

Trademarks = 3

Forward Citations = 174

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Richard J Austin (19 out of 23 patents)

Holger Wesche (18 out of 26 patents)

Bryan D Lemon (15 out of 23 patents)

4. Robert B Dubridge (10 out of 47 patents)

5. Jeanmarie Guenot (10 out of 16 patents)

6. Luke Evnin (8 out of 23 patents)

7. Patrick A Baeuerle (6 out of 35 patents)

8. Pui Seto (5 out of 5 patents)

9. Vanitha Ramakrishnan (3 out of 20 patents)

10. Shuoyen Jack Lin (1 out of 1 patent)

11. Kathryn Kwant (1 out of 1 patent)

12. Sony S Rocha (1 out of 1 patent)

13. Kevin Wright (0 patent)

14. Kathryn Kwant (0 patent)

23 patents: Sort by Forward Citations

1. 12415860 - Binding moiety for conditional activation of immunoglobulin molecules (2025-09-16),

2. 12371504 - Trispecific proteins and methods of use (2025-07-29),

3. 12195544 - EGFR binding proteins and methods of use (2025-01-14),

4. 12084518 - Trispecific binding proteins and methods of use (2024-09-10),

5. 11976125 - B cell maturation antigen binding proteins (2024-05-07),

6. 11807692 - DLL3 binding proteins and methods of use (2023-11-07),

7. 11623958 - Single chain variable fragment CD3 binding proteins (2023-04-11),

8. 11607453 - Mesothelin binding proteins (2023-03-21),

9. 11535668 - Inducible monovalent antigen binding protein (2022-12-27),

10. 11453716 - Single domain serum albumin binding protein (2022-09-27),

11. 11180563 - FLT3 binding proteins and methods of use (2021-11-23),

12. 11136403 - Trispecific proteins and methods of use (2021-10-05),

13. 10954311 - Trispecific binding proteins and methods of use (2021-03-23),

14. 10927180 - B cell maturation antigen binding proteins (2021-02-23),

15. 10849973 - Prostate specific membrane antigen binding protein (2020-12-01),

Harpoon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel T-cell engaging therapies to treat various forms of cancer. The company's proprietary technology platform, called TriTAC (Tri-specific T-cell Activating Construct), aims to harness the power of the patient's immune system to target and kill cancer cells. Harpoon Therapeutics is dedicated to advancing its pipeline of therapeutics with the goal of improving outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

23 Patents

#54 in South San Francisco, CA

#3,302 in California

#13,951 in US

#26,826 in the World

South San Francisco, CA, United States of America

Harpoon Therapeutics, Inc.

Forward Citations = 174

12 inventors:

Richard J Austin (19 out of 23 patents)

Holger Wesche (18 out of 26 patents)

Bryan D Lemon (15 out of 23 patents)

4. Robert B Dubridge (10 out of 47 patents)

5. Jeanmarie Guenot (10 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…